XBiotech (NASDAQ:XBIT) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of XBiotech (NASDAQ:XBIT – Get Rating) in a research note issued on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

XBiotech Stock Performance

Shares of XBIT stock opened at $3.38 on Thursday. XBiotech has a 52-week low of $3.00 and a 52-week high of $9.79. The company has a 50-day simple moving average of $3.84 and a two-hundred day simple moving average of $3.65. The company has a market capitalization of $102.89 million, a price-to-earnings ratio of -2.84 and a beta of 1.20.

Institutional Investors Weigh In On XBiotech

A number of institutional investors have recently added to or reduced their stakes in XBIT. Jane Street Group LLC bought a new stake in XBiotech in the 3rd quarter worth about $38,000. Bank of America Corp DE grew its position in shares of XBiotech by 155.1% during the 4th quarter. Bank of America Corp DE now owns 18,734 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 11,391 shares during the period. PDT Partners LLC grew its position in shares of XBiotech by 29.9% during the 2nd quarter. PDT Partners LLC now owns 16,976 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 3,912 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of XBiotech by 21.8% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 17,600 shares of the biopharmaceutical company’s stock valued at $99,000 after acquiring an additional 3,146 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of XBiotech by 72.8% during the 1st quarter. JPMorgan Chase & Co. now owns 15,093 shares of the biopharmaceutical company’s stock valued at $131,000 after acquiring an additional 6,360 shares during the period. 10.06% of the stock is owned by institutional investors.

XBiotech Company Profile

(Get Rating)

XBiotech, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.